Amylyx Pharmaceuticals (AMLX) Return on Capital Employed: 2022-2025
Historic Return on Capital Employed for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to -0.62%.
- Amylyx Pharmaceuticals' Return on Capital Employed rose 52.00% to -0.62% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.62%, marking a year-over-year increase of 52.00%. This contributed to the annual value of -0.96% for FY2024, which is 107.00% down from last year.
- According to the latest figures from Q3 2025, Amylyx Pharmaceuticals' Return on Capital Employed is -0.62%, which was up 41.34% from -1.06% recorded in Q2 2025.
- Amylyx Pharmaceuticals' Return on Capital Employed's 5-year high stood at 0.09% during Q4 2023, with a 5-year trough of -1.62% in Q4 2024.
- For the 3-year period, Amylyx Pharmaceuticals' Return on Capital Employed averaged around -0.64%, with its median value being -0.58% (2024).
- Per our database at Business Quant, Amylyx Pharmaceuticals' Return on Capital Employed surged by 107bps in 2023 and then slumped by 172bps in 2024.
- Quarterly analysis of 4 years shows Amylyx Pharmaceuticals' Return on Capital Employed stood at -0.84% in 2022, then spiked by 93bps to 0.09% in 2023, then plummeted by 172bps to -1.62% in 2024, then skyrocketed by 52bps to -0.62% in 2025.
- Its Return on Capital Employed stands at -0.62% for Q3 2025, versus -1.06% for Q2 2025 and -1.22% for Q1 2025.